Archive: November 03 2020
Find relevant news articles from other European projects, below:
Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:
CRS in CAR-T course freely available on the EHA Campus
The CRS in CAR-T module, part of the 8-course EHA Campus program dedicated to CAR-T cells, is now freely accessible by everyone - even non-EHA members. The course covers all aspects of Cytokine Release Syndrome (CRS), from pathophysiology to appropriate management. As this main complication of CAR-T cell therapy requires a multidisciplinary approach (including non-hematologists like intensivists, cardiologists, and neurologists whose educational needs are addressed in this course), EHA has made this module accessible by everyone.
Off-the-Shelf CAR T-Cell Products Show Potential in DLBCL
Loretta J. Nastoupil, MD, an assistant professor in the Department of Lymphoma/Myeloma at The University of Texas MD Anderson Cancer Center, discusses the use of off-the-shelf chimeric antigen receptor (CAR) T-cell products for the treatment of patients with diffuse large B-cell lymphoma (DLBCL) and other cancers.
Patient Perspectives on Cancer Immunotherapy at the 2020 CRI Virtual Immunothera...
At the 2020 CRI Virtual Immunotherapy Patient Summit, three CRI ImmunoAdvocates— cancer veterans treated with immunotherapy —share their experiences with cancer, immunotherapy, health care, and support.